Document Detail


In vivo modulation of Nogo-B attenuates neointima formation.
MedLine Citation:
PMID:  18781142     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nogo-B was recently identified as a novel vascular marker; the normally high vascular expression of Nogo-B is rapidly lost following vascular injury. Here we assess the potential therapeutic effects of Ad-Nogo-B delivery to injured vessels in vivo. Nogo-B overexpression following Ad-Ng-B infection of vascular smooth muscle cells (VSMCs) was shown to block proliferation and migration in a dose-dependent manner in vitro. We next assessed the effects of Ad-Ng-B treatment on neointima formation in two in vivo models of acute vascular injury. Adventitial delivery of Ad-Ng-B to wire-injured murine femoral arteries led to a significant decrease in the intimal area [0.014 mm(2) versus 0.030 mm(2) (P = 0.049)] and the intima:media ratio [0.78 versus 1.67 (P = 0.038)] as compared to the effects of Ad-beta-Gal control virus at 21 days after injury. Similarly, lumenal delivery of Ad-Ng-B to porcine saphenous veins prior to carotid artery grafting significantly reduced the intimal area [2.87 mm(2) versus 7.44 mm(2) (P = 0.0007)] and the intima:media ratio [0.32 versus 0.55 (P = 0.0044)] as compared to the effects following the delivery of Ad- beta-Gal, at 28 days after grafting. Intimal VSMC proliferation was significantly reduced in both the murine and porcine disease models. Gene delivery of Nogo-B exerts a positive effect on vascular injury-induced remodeling and reduces neointimal development in two arterial and venous models of vascular injury.
Authors:
Angelika B Kritz; Jun Yu; Paulette L Wright; Song Wan; Sarah J George; Crawford Halliday; Ning Kang; William C Sessa; Andrew H Baker
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2008-09-09
Journal Detail:
Title:  Molecular therapy : the journal of the American Society of Gene Therapy     Volume:  16     ISSN:  1525-0024     ISO Abbreviation:  Mol. Ther.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-28     Completed Date:  2009-02-03     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  100890581     Medline TA:  Mol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1798-804     Citation Subset:  IM    
Affiliation:
British Heart Foundation Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow, UK. ab11f@clinmed.gla.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae / genetics
Animals
Carotid Arteries / metabolism,  pathology,  surgery
Cell Proliferation
Cells, Cultured
Chemotaxis
Constriction, Pathologic / pathology,  prevention & control
Disease Models, Animal
Femoral Artery / metabolism,  pathology
Gene Transfer Techniques
Genetic Vectors
Graft Occlusion, Vascular / pathology,  prevention & control
Humans
Mice
Mice, Inbred C57BL
Mice, Knockout
Muscle, Smooth, Vascular / metabolism*,  pathology
Myelin Proteins / biosynthesis*,  genetics
Saphenous Vein / metabolism,  pathology
Swine
Tunica Intima / metabolism*,  pathology
Tunica Media / metabolism*,  pathology
Grant Support
ID/Acronym/Agency:
4542/06M//British Heart Foundation; HL64793/HL/NHLBI NIH HHS; N01-HV-28186/HV/NHLBI NIH HHS; P01 HL70295/HL/NHLBI NIH HHS; R01 HL061371/HL/NHLBI NIH HHS; R01 HL064793/HL/NHLBI NIH HHS; R01 HL081190/HL/NHLBI NIH HHS; R01 HL096670/HL/NHLBI NIH HHS; R01 HL57665/HL/NHLBI NIH HHS; R01 HL61371/HL/NHLBI NIH HHS; R37 HL061371/HL/NHLBI NIH HHS; //Medical Research Council
Chemical
Reg. No./Substance:
0/Myelin Proteins; 0/Nogo protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in ...
Next Document:  Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice.